XML 23 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued Operations
3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

3. DISCONTINUED OPERATIONS

Mural Oncology Separation

On November 15, 2023, the Company completed the separation of its oncology business into Mural Oncology plc (“Mural”), a new, independent, publicly-traded company (the “Separation”). In connection with the Separation, the Company and Mural entered into, among other agreements: a separation agreement; a tax matters agreement; and an employee matters agreement, which are described in Note 3, Discontinued Operations in the “Notes to Consolidated Financial Statements” accompanying the Annual Report.

 

Discontinued Operations

The Company determined that the Separation met the criteria for classification of the oncology business as discontinued operations in accordance with Topic 205. The following summarizes the loss from discontinued operations for the three months ended March 31, 2025 and 2024:

 

 

 

Three Months Ended
March 31,

 

(In thousands)

 

2025

 

 

2024

 

Operating expenses from discontinued operations

 

 

 

 

 

 

Cost of goods manufactured

 

$

 

 

$

 

Research and development

 

 

 

 

 

2,516

 

Selling, general and administrative

 

 

 

 

 

 

Total operating expenses from discontinued operations

 

 

 

 

 

2,516

 

Operating loss from discontinued operations

 

 

 

 

 

(2,516

)

Income tax benefit from discontinued operations

 

 

 

 

 

(396

)

Net loss and comprehensive loss from discontinued operations

 

$

 

 

$

(2,120

)